Pharmaceuticals and Biotechnology Sector News
The latest news stories on Pharmaceuticals and Biotechnology sector from Fairfax Media news sources are listed on this page by relevance to the sector.
Please click the Date link to sort by most recent.
Latest Pharmaceuticals and Biotechnology Sector NewsSort by Date | Sort by Relevance
Rebel Progen shareholders claim support
SMH 12:00am 05 Jan 2009 A dissident group of shareholders in Progen Pharmaceuticals says it has substantial support to unseat the current board of the cancer drug developer on Friday.
Biotech proves defensive against tough 2008 market
SMH 12:00am 01 Jan 2009 Sharp gains in shares of biotechnology heavyweights mitigated the wider sector's decline in 2008. Biotech stocks proved to be one of the safest investments this year, as strong drug sales and the potential for large buyout deals defended the sector from broader market collapse.
Class action begins over Pan handling
TheAge 12:00am 24 Dec 2008 The Federal Government faces a class action over its handling of the Pan Pharmaceuticals health scare after it declined to negotiate with Pan associates.
Pan associates go after Government
SMH 12:00am 24 Dec 2008 THE Federal Government is facing a class action over its handling of the Pan Pharmaceuticals health scare after it declined to negotiate with Pan associates who claim they are $120 million out of pocket.
People sue government over Pan collapse
SMH 12:00am 23 Dec 2008 People who lost money when Pan Pharmaceuticals collapsed in 2005 have filed a lawsuit against the Commonwealth government.
Progen and Avexa agree to merge
SMH 12:00am 22 Dec 2008 Progen Pharmaceuticals Ltd and Avexa Ltd have agreed to merge to create one of the biggest biotechnology groups in Australia.
Progen to buy Avexa at discount
SMH 12:00am 22 Dec 2008 Drug maker Progen Pharmaceuticals's discounted offer to buy Avexa has received a frosty reception from investors.
Genentech continues early-stage colon cancer study
SMH 12:00am 21 Oct 2008 Biotechnology company Genentech Inc. said Monday a late-stage study of Avastin focusing on early-stage colon cancer will continue, following an independent safety analysis.
Genentech 3Q profit rises, meets forecast
SMH 12:00am 15 Oct 2008 Genentech Inc.'s third-quarter profit fell rose 6.7 percent on sales of key cancer drugs, the biotechnology company said Tuesday, matching Wall Street's profit forecasts.
Ahead of the Bell: Genentech
SMH 12:00am 15 Oct 2008 Wall Street gave a nod of approval to Genentech Inc.'s third-quarter financial results Tuesday, with several analysts saying they could be a key factor in prompting Roche to return with a higher bid for the biotechnology company.
- Also see:
- Health Care Companies List
